Log In
Print
BCIQ
Print
Print this Print this
 

PEGPH20 (formerly PEGrHuPH20)

  Manage Alerts
Collapse Summary General Information
Company Halozyme Therapeutics Inc.
DescriptionRecombinant human PH20 hyaluronidase enzyme conjugated to polyethylene glycol (PEG)
Molecular Target Hyaluronan
Mechanism of ActionDegrades hyaluronan
Therapeutic ModalityBiologic: Enzyme
Latest Stage of DevelopmentPhase II
Standard IndicationPancreatic cancer
Indication DetailsFirst-line treatment of stage IV metastatic pancreatic cancer; Treat pancreatic cancer; Treat previously untreated metastatic pancreatic cancer; Ttreat metastatic pancreatic cancer in combination with nab-paclitaxel and gemcitabine
Regulatory Designation

U.S. - Fast Track (Ttreat metastatic pancreatic cancer in combination with nab-paclitaxel and gemcitabine);
U.S. - Fast Track (First-line treatment of stage IV metastatic pancreatic cancer)

Partner


 Product Details
 Archive Items are loading loading
Get a free BioCentury trial today